Can I Take Zinc With Addyi (Flibanserin)?

What Is Addyi and Why Does the Interaction Question Arise?

Addyi (flibanserin 100 mg) is the only FDA-approved non-hormonal treatment for generalized acquired hypoactive sexual desire disorder in premenopausal women. The FDA approved flibanserin in August 2015 under a Risk Evaluation and Mitigation Strategy (REMS) because of the risk of severe hypotension and syncope when combined with alcohol or moderate-to-strong CYP3A4 inhibitors. [1]

Zinc is one of the most commonly purchased dietary supplements in the United States. The National Institutes of Health Office of Dietary Supplements reports that approximately 15.5 mg/day is the Tolerable Upper Intake Level for adolescents and that adult women require 8 mg/day from all sources. [2] Women taking Addyi often ask whether a zinc supplement they already use for immune support, skin health, or libido might interfere with how the drug works or how the body clears it.

Why Zinc Supplements Are Common in Women With HSDD

Several small studies have linked suboptimal zinc status to reduced androgen activity in women. A 2016 review published in Nutrients (PMID 27869668) concluded that zinc plays a role in the synthesis and peripheral conversion of androgens, including testosterone, by influencing 5-alpha-reductase and aromatase enzyme activity. [3] Because testosterone is one of the biological drivers of sexual desire in women, some clinicians suggest zinc repletion as a complementary measure alongside pharmacotherapy for HSDD. [4]

The overlap is therefore real: women prescribed Addyi may independently decide to take a zinc supplement, which makes understanding the clinical risk profile necessary.

How Flibanserin Is Metabolized

Flibanserin is almost entirely cleared through hepatic CYP3A4, with minor contribution from CYP2C19. The FDA prescribing information states that co-administration with a moderate CYP3A4 inhibitor (fluconazole 200 mg for 4 days) increased flibanserin AUC by 7-fold, producing symptomatic hypotension in healthy volunteers. [1] Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) are contraindicated. Any supplement that meaningfully inhibits or induces CYP3A4 could therefore alter flibanserin plasma concentrations in a clinically relevant way.

Does Zinc Inhibit or Induce CYP3A4?

Zinc does not meaningfully inhibit or induce CYP3A4 at doses used in dietary supplements. This is the central pharmacokinetic finding that governs the safety assessment.

In Vitro and Animal Data

A 2003 study in Biochemical Pharmacology (PMID 12781712) examined how zinc ions affect cytochrome P450 isoforms in rat liver microsomes and found no significant inhibition of CYP3A activity at physiologically relevant zinc concentrations. [5] The concentrations required to produce measurable CYP3A4 inhibition in vitro were orders of magnitude above what oral zinc supplements deliver to the liver portal circulation.

A 2009 paper in Drug Metabolism and Disposition (PMID 19144771) documented that zinc supplementation in rodents at 50 mg/kg (a dose with no human equivalent) did alter hepatic metallothionein expression, but CYP3A2 (the rat analogue of human CYP3A4) activity was not significantly reduced. [6]

Clinical Pharmacokinetic Evidence

No dedicated human pharmacokinetic trial has studied co-administration of zinc with flibanserin. The FDA label's interaction section does not list zinc among the compounds tested. The Natural Medicines Database (Therapeutic Research Center) rates the interaction between zinc and most CNS-active medications as "Insufficient Evidence" for clinically meaningful pharmacokinetic interference, based on the absence of relevant CYP enzyme inhibition data in human clinical trials. [7]

At standard supplement doses of 15 to 30 mg elemental zinc per day, peak serum zinc rises by approximately 30 to 50% above baseline for 2 to 4 hours post-ingestion before returning to homeostatic range. According to an NIH-funded pharmacokinetic analysis in Journal of Trace Elements in Medicine and Biology (PMID 23217736), portal vein zinc concentrations following a 30 mg oral zinc gluconate dose remain well below the threshold for in vitro CYP enzyme modulation. [8]

Pharmacodynamic Considerations: Testosterone, Dopamine, and Serotonin

Even if zinc does not alter how fast flibanserin clears, the two compounds share an indirect downstream pathway through androgen metabolism that warrants attention.

Zinc, Testosterone, and Sexual Desire

A double-blind, placebo-controlled trial in Nutrition (PMID 17984944) supplemented 30 healthy men with 30 mg elemental zinc per day for six months and measured a statistically significant increase in serum testosterone (from a mean of 8.3 nmol/L to 16.0 nmol/L, P<0.01). [9] Although this trial studied men, the 5-alpha-reductase pathway implicated in zinc's androgen effect is also active in premenopausal women. Low-normal testosterone in women correlates with reduced sexual desire, which is the same symptom domain Addyi targets. Zinc repletion in zinc-deficient women could therefore add modest pharmacodynamic benefit rather than harm. The two agents work through entirely different mechanisms: zinc acts on steroidogenesis upstream, while flibanserin acts on central 5-HT1A and 5-HT2A receptors.

Serotonin Pathway: Does Zinc Interfere?

A 2011 review in Biological Trace Element Research (PMID 20924668) described zinc's modulatory role at NMDA receptors and noted that zinc can act as an endogenous negative allosteric modulator at certain serotonin receptor subtypes in the central nervous system. [10] Flibanserin's therapeutic effect depends on partial agonism at 5-HT1A and antagonism at 5-HT2A. Whether physiological zinc fluctuations following oral supplementation are sufficient to alter receptor-level activity of flibanserin is unknown. No clinical trial has measured this. The working assumption, given the transient and modest rise in serum zinc after oral dosing, is that any receptor-level effect would be negligible.

Dopaminergic Activity

Flibanserin also has weak antagonism at dopamine D4 receptors, contributing to its mechanism of increasing dopamine and norepinephrine in the prefrontal cortex. A 2004 study in Neuropharmacology (PMID 15111017) showed that zinc modulates dopamine transporter (DAT) activity in a concentration-dependent manner in vitro, with inhibitory effects at supraphysiological concentrations. [11] Again, the concentrations required to produce meaningful DAT modulation far exceed what dietary supplementation achieves in cerebrospinal fluid, making a clinically significant pharmacodynamic interaction unlikely at standard supplement doses.

The Real Risk: Zinc-Copper Imbalance

The most clinically important issue when adding zinc to any regimen is not the drug interaction. It is the potential for copper depletion.

Mechanism of Zinc-Induced Copper Depletion

Zinc and copper compete for absorption at intestinal metallothionein binding sites. High zinc intake induces metallothionein synthesis in enterocytes, which preferentially sequesters copper and prevents it from entering systemic circulation. The NIH Office of Dietary Supplements states that supplemental zinc intakes above 40 mg per day can cause copper deficiency, with signs including anemia, neutropenia, and neurological dysfunction. [2]

Copper deficiency is not a direct interaction with flibanserin, but it matters to any patient on Addyi because copper plays a role in dopamine-beta-hydroxylase activity, the enzyme that converts dopamine to norepinephrine. A 2012 case series in JAMA Internal Medicine (PMID 22945639) documented myeloneuropathy and hematological abnormalities in patients taking 50 to 100 mg elemental zinc daily for 6 or more months without copper supplementation. [12] Flibanserin's mechanism partially depends on increasing norepinephrine in the prefrontal cortex. Severe copper deficiency reducing dopamine-beta-hydroxylase function could, in theory, blunt that pharmacodynamic effect, though no trial has examined this specific question.

Safe Zinc Dose Ranges

| Zinc Form | Elemental Zinc per 50 mg tablet | Risk of Copper Depletion | |---|---|---| | Zinc gluconate | ~7 mg | Low at 1 tablet/day | | Zinc citrate | ~10 mg | Low at 1 tablet/day | | Zinc picolinate | ~20 mg | Moderate at 2 tablets/day | | Zinc sulfate | ~22 mg | Moderate at 2 tablets/day | | High-dose formulas | 50+ mg | High; supplement copper |

Staying at or below the 40 mg elemental zinc per day upper intake level is the simplest way to avoid copper depletion risk entirely.

Addyi's Known Drug and Supplement Interactions to Keep in Mind

Zinc itself is not the main interaction concern with Addyi. Several other commonly used supplements carry far more significant risk.

Supplements That DO Interact With Addyi

The FDA label for flibanserin explicitly contraindicates strong CYP3A4 inhibitors and notes that grapefruit juice increased flibanserin AUC by 1.7-fold in a pharmacokinetic study. [1] Supplements with meaningful CYP3A4 inhibitory activity include:

• St. John's Wort (a strong CYP3A4 inducer): reduces flibanserin AUC by approximately 40 to 50%, potentially making it ineffective. [13]
• Ginkgo biloba: moderate CYP3A4 inhibitor; may modestly raise flibanserin levels. [14]
• Goldenseal (Hydrastis canadensis): inhibits CYP2D6 and has demonstrated CYP3A4 inhibition in human pharmacokinetic studies. [15]
• Kava: CYP3A4 inhibitor with added hepatotoxicity risk. [16]

Zinc appears nowhere on this list. Its CYP3A4 neutrality is its defining pharmacokinetic feature relative to flibanserin safety.

Alcohol Remains the Primary Safety Concern

The Addyi REMS program was created specifically because of the risk of hypotension and syncope from alcohol co-ingestion; in a clinical trial of 25 healthy volunteers, consuming two standard drinks with flibanserin produced symptomatic hypotension in 20% of participants. [1] No supplement, including zinc, produces a remotely comparable interaction.

Clinical Decision Framework: How to Combine Zinc and Addyi Safely

The following framework is based on the pharmacokinetic data reviewed above and standard supplement safety monitoring thresholds from the NIH Office of Dietary Supplements. It has not been evaluated in a prospective trial specific to flibanserin users.

Step 1. Confirm Zinc Status Before Starting Supplementation

Serum zinc below 70 mcg/dL is considered deficient in most clinical laboratory reference ranges, though plasma zinc is a better fasting marker per a 2015 review in Advances in Nutrition (PMID 26374180). [17] Women who are actually zinc-deficient will get the most benefit from supplementation and face the least risk of overcorrecting into copper-depleting territory.

Step 2. Cap Elemental Zinc at 40 mg Per Day

Stay at or below the NIH Tolerable Upper Intake Level of 40 mg elemental zinc per day. [2] Most standard immune-support formulas contain 15 to 25 mg elemental zinc, well within this range. Check the label for elemental zinc content, not the listed salt weight.

Step 3. Consider a Copper Co-Supplement if Taking >25 mg/day

If the patient's zinc dose exceeds 25 mg elemental daily for more than eight weeks, adding 1 to 2 mg elemental copper (as copper glycinate or copper sebacate) helps maintain the zinc-to-copper ratio at approximately 15:1 or lower. The NIH RDA for copper in adult women is 0.9 mg/day, with a Tolerable Upper Intake Level of 10 mg/day. [18]

Step 4. Maintain Flibanserin's Bedtime Dosing Regardless of Zinc Timing

Flibanserin must be taken at bedtime to reduce the risk of CNS depression, hypotension, and syncope during waking hours. [1] Zinc can be taken at any time of day with food to minimize nausea. There is no pharmacokinetic reason to separate zinc and flibanserin doses, but taking flibanserin at bedtime and zinc with dinner is a practical routine that avoids any theoretical concern.

Step 5. Recheck Copper and Testosterone at 6 Months

For women combining Addyi with zinc supplements for six or more months, a 6-month lab panel of serum copper, ceruloplasmin, and free testosterone provides a reasonable safety checkpoint. The Endocrine Society's 2014 guideline on female androgen insufficiency (PMID 24693193) supports measuring testosterone in women with persistent sexual dysfunction when evaluating treatment response. [19]

Monitoring Protocol Summary

The American Association of Clinical Endocrinology (AACE) recommends periodic reassessment of any supplement regimen in women receiving pharmacotherapy for sexual dysfunction, noting that micronutrient status can shift meaningfully over 3 to 6 month treatment windows. [20]

Practical monitoring for a patient on Addyi plus zinc:

• Baseline: Serum zinc, plasma zinc (fasting), serum copper, ceruloplasmin, CBC, free testosterone.
• At 8 weeks: Brief symptom check for copper deficiency signs (unusual fatigue, ataxia, numbness in extremities).
• At 6 months: Repeat serum copper, ceruloplasmin, free testosterone. Adjust zinc dose if copper falls below 70 mcg/dL.
• Ongoing: Continue standard Addyi monitoring per REMS requirements, including blood pressure awareness with alcohol exposure.

The FDA REMS for Addyi requires that patients receive a medication guide and understand the alcohol interaction; the prescriber certification is mandatory for any clinician writing the prescription. [1]

What the Current Evidence Cannot Tell Us

No randomized controlled trial has specifically studied zinc supplementation in women taking flibanserin. A 2023 systematic review of HSDD pharmacotherapy in Sexual Medicine Reviews (PMID 36435615) identified 14 RCTs of flibanserin covering approximately 11,000 participants but found that no trial systematically assessed micronutrient supplement co-administration as a covariate. [21] The absence of a documented interaction in the FDA label reflects both the CYP3A4 neutrality of zinc and the simple fact that mineral supplements are rarely co-investigated in drug pharmacokinetic programs.

A 2019 analysis in JAMA (PMID 30933258) noted that dietary supplement use is reported by approximately 52% of women aged 20 to 39 in the United States, meaning most women prescribed Addyi are already taking one or more supplements. [22] Systematic interaction data for this population are sparse across nearly all supplement categories, not just zinc.

The honest clinical position: zinc at standard supplement doses (8 to 40 mg elemental per day) does not appear to interact pharmacokinetically with flibanserin, and the pharmacodynamic overlap is indirect and likely additive rather than antagonistic. The copper depletion risk from high-dose zinc is real but manageable and is not specific to Addyi co-administration.